News | Blood Testing | September 07, 2017

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test

Nine-minute test designed to aid in faster diagnosis of heart attacks

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test

September 7, 2017 — In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U.S. Food and Drug Administration (FDA)-cleared high sensitive Elecsys Troponin T Gen 5 blood test (Troponin T Gen 5 or TnT Gen 5) to aid in the diagnosis of heart attacks.  The new nine-minute test offers faster answers clinicians can use when diagnosing heart attack.

“This next-generation Troponin T assay from Roche Diagnostics allows clinicians to make better choices when identifying heart attack and thereby enhances our diagnostic abilities for our patients, especially as we use the gender-specific cutoffs,” said Louis Isaacson, DO, director of emergency services at Florida Medical Center. “Using the TnT Gen 5 test, we can rule in or rule out cardiac disease; in particular, acute myocardial infarction.”

Every 43 seconds someone in the United States has a heart attack, or acute myocardial infarction (AMI), which occurs when the blood supply to an area of the heart is interrupted. The longer the heart is without proper blood supply, the greater the damage. Troponin, a specific marker of cardiac cell death, is released into the blood stream when cardiac cells are being damaged. By detecting small elevations of troponin, the highly sensitive Troponin T Gen 5 test aids in the diagnosis of a heart attack and can help save lives.

Using the hsTnT (TnT Gen 5) test, in combination with an electrocardiogram (ECG) and clinical signs of inadequate blood supply, allows emergency department physicians to stratify patients according to risk in order to determine the best care plan for individual patients.

“Our goal is to be able to send more patients home for outpatient cardiology follow-up rather than have them deal with an unnecessary hospitalization, said Trey Abshier, CEO of Florida Medical Center. “We want to focus on continuing to set the standard for the diagnosis and treatment of acute cardiac problems in the state in order to better serve the patients who entrust us with their care.”

For more information: www.usdiagnostics.roche.com

Related Content

Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing| March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing| January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing| July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing| March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Frost & Sullivan, biomarkers, cardiac disease diagnosis, analysis
News | Blood Testing| January 12, 2016
Even though brain natriuretic peptide (BNP)/pro-BNP and troponin biomarkers are the gold standard for cardiac disease...
Overlay Init